Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Background/Aims Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods T...

Full description

Bibliographic Details
Main Authors: Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2020-07-01
Series:Clinical and Molecular Hepatology
Subjects:
entecavir
tenofovir
lamivudine
antiviral drug resistance
adefovir
Online Access:http://e-cmh.org/upload/pdf/cmh-2019-0044n.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-2019-0044n.pdf

Similar Items